NL301089I1 - - Google Patents

Info

Publication number
NL301089I1
NL301089I1 NL301089C NL301089C NL301089I1 NL 301089 I1 NL301089 I1 NL 301089I1 NL 301089 C NL301089 C NL 301089C NL 301089 C NL301089 C NL 301089C NL 301089 I1 NL301089 I1 NL 301089I1
Authority
NL
Netherlands
Prior art keywords
ides polypeptide
medicament
disease
prevention
manufacture
Prior art date
Application number
NL301089C
Other languages
English (en)
Other versions
NL301089I2 (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511769A external-priority patent/GB0511769D0/en
Priority claimed from GB0605781A external-priority patent/GB0605781D0/en
Application filed filed Critical
Publication of NL301089I1 publication Critical patent/NL301089I1/nl
Publication of NL301089I2 publication Critical patent/NL301089I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL301089C 2005-06-09 2021-01-14 imlifidase NL301089I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0511769A GB0511769D0 (en) 2005-06-09 2005-06-09 Treatment
GB0605781A GB0605781D0 (en) 2006-03-22 2006-03-22 Treatment
PCT/EP2006/005454 WO2006131347A2 (en) 2005-06-09 2006-06-08 Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection

Publications (2)

Publication Number Publication Date
NL301089I1 true NL301089I1 (nl) 2021-01-20
NL301089I2 NL301089I2 (nl) 2021-02-04

Family

ID=36952007

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301089C NL301089I2 (nl) 2005-06-09 2021-01-14 imlifidase

Country Status (14)

Country Link
US (1) US8133483B2 (nl)
EP (1) EP1901773B1 (nl)
JP (1) JP5427409B2 (nl)
CN (1) CN105770871A (nl)
AT (1) ATE548049T1 (nl)
AU (1) AU2006256891B2 (nl)
BE (1) BE2021C505I2 (nl)
CA (1) CA2611646C (nl)
ES (1) ES2380950T3 (nl)
FR (1) FR21C1004I2 (nl)
NL (1) NL301089I2 (nl)
PL (1) PL1901773T3 (nl)
PT (1) PT1901773E (nl)
WO (1) WO2006131347A2 (nl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216863B8 (en) * 2000-12-21 2008-03-20 Id Biomedical Corporation Streptococcus pyogenes antigens and corresponding DNA fragments
EP2144681A4 (en) 2007-05-04 2011-10-05 Kurt G I Nilsson MATERIAL FOR THE DEPOSITION OF A BIOMOLECULAR
CN101903401B (zh) 2007-12-21 2013-06-05 罗切格利卡特公司 抗体的稳定性试验
CN102308216B (zh) 2009-02-09 2014-07-09 罗切格利卡特公司 免疫球蛋白糖基化模式分析
AU2010240486B2 (en) * 2009-04-22 2014-09-18 Ofir Menashe Microorganism comprising particles and uses of same
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
DK3411389T3 (da) 2016-02-04 2021-06-21 Genovis Ab Nye streptokokproteaser
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
AU2020323542A1 (en) * 2019-08-01 2022-03-17 Memorial Hospital For Cancer And Allied Diseases Cells for improved immunotherapy and uses thereof
JP2022550930A (ja) 2019-12-06 2022-12-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
US20230374083A1 (en) * 2020-09-21 2023-11-23 Shanghai Bao Pharmaceuticals Co., Ltd. Pharmaceutical combination and use thereof
AU2021358957A1 (en) 2020-10-07 2023-06-08 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21
CA3216491A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
US12091694B2 (en) 2022-11-18 2024-09-17 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
WO2024148276A1 (en) 2023-01-06 2024-07-11 Seismic Therapeutic, Inc. Protease variants and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6158501A (en) * 2000-05-12 2001-11-26 Beth Israel Hospital Compositions and methods for achieving immune suppression
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein

Also Published As

Publication number Publication date
CA2611646C (en) 2015-08-11
US8133483B2 (en) 2012-03-13
BE2021C505I2 (nl) 2021-05-31
AU2006256891A1 (en) 2006-12-14
CA2611646A1 (en) 2006-12-14
WO2006131347A2 (en) 2006-12-14
FR21C1004I2 (fr) 2022-01-14
EP1901773B1 (en) 2012-03-07
US20100303781A1 (en) 2010-12-02
NL301089I2 (nl) 2021-02-04
PT1901773E (pt) 2012-06-06
WO2006131347A3 (en) 2007-05-31
EP1901773A2 (en) 2008-03-26
AU2006256891B2 (en) 2011-08-04
ES2380950T3 (es) 2012-05-21
ATE548049T1 (de) 2012-03-15
CN105770871A (zh) 2016-07-20
FR21C1004I1 (nl) 2021-03-26
PL1901773T3 (pl) 2012-09-28
JP5427409B2 (ja) 2014-02-26
JP2008542418A (ja) 2008-11-27

Similar Documents

Publication Publication Date Title
BE2021C505I2 (nl)
WO2008071418A3 (en) Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases
TW200626171A (en) Fixed dosing of HER antibodies
TW200738270A (en) Method of treating depression using a TNFα antibody
MX341370B (es) Antagonistas anti - beta7 humanizados y usos para los mismos.
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX2009012343A (es) Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
TW200709817A (en) Platform antibody compositions
MY149630A (en) Antibodies against amyloid-beta peptide
WO2006127757A3 (en) Interferon-igg fusion
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
MY181969A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
WO2007073497A3 (en) Calcium channel antagonists
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
TW200740844A (en) Novel MAdCAM antibodies
HK1125855A1 (en) Use of oligouronates for treating mucus hyperviscosity
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
MX2010006823A (es) Metodos para el tratamiento de la gota.
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
MX2011011729A (es) Anticuerpo anti il-17f y metodos de uso de los mismos.
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
WO2007075852A3 (en) Calcium channel antagonists
MY149492A (en) Immunoglobulins directed against nogo
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
EA200801180A1 (ru) Селективные пептидные агонисты рецептора vpac2